Clinical Trials in Roanoke, Virginia
3 recruiting
Showing 1–17 of 17 trials
Recruiting
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast CarcinomaColorectal CarcinomaMelanoma+2 more
Wake Forest University Health Sciences2,000 enrolled467 locationsNCT06418204
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled475 locationsNCT05564377
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC675 enrolled96 locationsNCT07190248
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled257 locationsNCT06312176
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled234 locationsNCT06966700
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting
Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb530 enrolled184 locationsNCT06646276
Recruiting
Not Applicable
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Breast CancerCognitive Impairments
NRG Oncology386 enrolled680 locationsNCT05896189
Recruiting
Phase 1Phase 2
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Breast CancerBreast Neoplasms
Pfizer100 enrolled159 locationsNCT06966453
Recruiting
Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
Breast CancerDepression
NRG Oncology402 enrolled277 locationsNCT06748222
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled315 locationsNCT06103864
Recruiting
Phase 3
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
OsteosarcomaMetastatic Malignant Neoplasm in the LungMetastatic Osteosarcoma
Children's Oncology Group62 enrolled232 locationsNCT05235165
Recruiting
Phase 2
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Breast CancerEsophageal CancerGastric Cancer+1 more
Jazz Pharmaceuticals200 enrolled21 locationsNCT06695845
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
AstraZeneca878 enrolled282 locationsNCT06627647
Recruiting
Phase 3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals550 enrolled166 locationsNCT06435429
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557